37 related articles for article (PubMed ID: 23473612)
1. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.
Lièvre A; Artru P; Guiu M; Laurent-Puig P; Merlin JL; Sabourin JC; Viguier J; Bastie A; Seronde A; Ducreux M
Eur J Cancer; 2013 Jun; 49(9):2126-33. PubMed ID: 23473612
[TBL] [Abstract][Full Text] [Related]
2. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
3. [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].
Bibeau F; Louvet C; Afchain P; Mitry E; Artru P; André T
Bull Cancer; 2012; 99(7-8):743-51. PubMed ID: 22735045
[TBL] [Abstract][Full Text] [Related]
4. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.
Mariani P; Lae M; Degeorges A; Cacheux W; Lappartient E; Margogne A; Pierga JY; Girre V; Mignot L; Falcou MC; Salmon RJ; Delattre O; De Cremoux P
Anticancer Res; 2010 Oct; 30(10):4229-35. PubMed ID: 21036746
[TBL] [Abstract][Full Text] [Related]
5. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
6. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
7. KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.
Carter GC; Landsman-Blumberg PB; Johnson BH; Juneau P; Nicol SJ; Li L; Shankaran V
J Exp Clin Cancer Res; 2015 Mar; 34(1):29. PubMed ID: 25888436
[TBL] [Abstract][Full Text] [Related]
8. Personalized cancer treatment and the myth of KRAS wild-type colon tumors.
Parsons BL; Myers MB
Discov Med; 2013 Apr; 15(83):259-67. PubMed ID: 23636143
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
Normanno N; Pinto C; Castiglione F; Bardelli A; Gambacorta M; Botti G; Nappi O; Siena S; Ciardiello F; Taddei G; Marchetti A
PLoS One; 2011; 6(12):e29146. PubMed ID: 22216189
[TBL] [Abstract][Full Text] [Related]
10. Intratumorous heterogeneity for RAS mutations in a treatment-naïve colorectal tumour.
Lunke S; Lee B; Kranz S; Gibbs P; Waring P; Christie M
J Clin Pathol; 2017 Aug; 70(8):720-723. PubMed ID: 28314739
[TBL] [Abstract][Full Text] [Related]
11. [Detection of RAS genes mutation using the Cobas
Albertini AF; Raoux D; Neumann F; Rossat S; Tabet F; Pedeutour F; Duranton-Tanneur V; Kubiniek V; Vire O; Weinbreck N
Bull Cancer; 2017; 104(7-8):662-674. PubMed ID: 28688743
[TBL] [Abstract][Full Text] [Related]
12. Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer.
Chong CY; Jalali A; Wong HL; Loft M; Wong R; Lee M; Gately L; Hong W; Shapiro J; Kosmider S; Tie J; Ananda S; Yeung JM; Ma B; Burge M; Jennens R; Tran B; Lee B; Lim L; Dean A; Nott L; Gibbs P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e363-e368. PubMed ID: 35073441
[TBL] [Abstract][Full Text] [Related]
13.
Greenbaum A; Wiggins C; Meisner AL; Rojo M; Kinney AY; Rajput A
Heliyon; 2017 Nov; 3(11):e00448. PubMed ID: 29202108
[TBL] [Abstract][Full Text] [Related]
14. Anti-Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer-Another Piece to the Puzzle.
Morano F; Pietrantonio F
JAMA Netw Open; 2023 Sep; 6(9):e2333488. PubMed ID: 37721757
[No Abstract] [Full Text] [Related]
15. KRAS Testing: Optimizing Cancer Therapy.
Carlson B
Biotechnol Healthc; 2009; 6(5):7-9. PubMed ID: 22478793
[No Abstract] [Full Text] [Related]
16. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.
Penault-Llorca F; Radosevic-Robin N
Transl Lung Cancer Res; 2018 Dec; 7(6):716-721. PubMed ID: 30505716
[TBL] [Abstract][Full Text] [Related]
18. In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant
Ng AWR; Tan PJ; Hoo WPY; Liew DS; Teo MYM; Siak PY; Ng SM; Tan EW; Abdul Rahim R; Lim RLH; Song AAL; In LLA
PeerJ; 2018; 6():e5056. PubMed ID: 30042874
[TBL] [Abstract][Full Text] [Related]
19. Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
Thiebault Q; Defossez G; Karayan-Tapon L; Ingrand P; Silvain C; Tougeron D
BMC Cancer; 2017 Nov; 17(1):765. PubMed ID: 29137623
[TBL] [Abstract][Full Text] [Related]
20. RAS testing in metastatic colorectal cancer: advances in Europe.
Van Krieken JH; Rouleau E; Ligtenberg MJ; Normanno N; Patterson SD; Jung A
Virchows Arch; 2016 Apr; 468(4):383-96. PubMed ID: 26573425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
